Polynovo Limited ( (AU:PNV) ) just unveiled an update.
PolyNovo Limited reported significant growth in its half-year results for FY25, with record sales of A$54.1m, a 28.1% increase from the same period last year. The company achieved a net profit after tax of A$3.3m, marking a 23.9% rise. Key achievements include strong NovoSorb MTX sales in the U.S., advancements in product development, and progress in clinical trials for burn treatments. The company is also expanding its manufacturing and innovation capabilities and focusing on market development efforts in the U.S. and other regions.
More about Polynovo Limited
PolyNovo Limited is a Melbourne-based, disruptive ASX 200 medical technology company focused on simplifying the management of acute complex wounds. Known for its NovoSorb range, the company offers bio-resorbable polymers for dermal regeneration used in surgeries, trauma, and burns. PolyNovo has treated over 67,000 patients in 46 countries and is expanding its product range and market reach.
YTD Price Performance: 6.73%
Average Trading Volume: 4,170
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $856.4M
For an in-depth examination of PNV stock, go to TipRanks’ Stock Analysis page.